# Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

> **NCT05859477** · PHASE2 · UNKNOWN · sponsor: **Kidney Cancer Research Bureau** · enrollment: 23 (estimated)

## Conditions studied

- Metastatic Gastric Cancer
- PD-L1 Gene Amplification
- FGFR2 Amplification

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT05859477
- **Lead sponsor:** Kidney Cancer Research Bureau
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-05
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05859477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05859477, "Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05859477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*